These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15176917)

  • 21. An analysis of the topography, severity, potential sources of reinforcement, and treatments utilized for skin picking in Prader-Willi syndrome.
    Hustyi KM; Hammond JL; Rezvani AB; Hall SS
    Res Dev Disabil; 2013 Sep; 34(9):2890-9. PubMed ID: 23810929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
    Bays HE; Gadde KM
    Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topiramate for binge-eating disorder associated with obesity.
    Tata AL; Kockler DR
    Ann Pharmacother; 2006 Nov; 40(11):1993-7. PubMed ID: 17047134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topiramate and phentermine: a long story...
    Prescrire Int; 2013 Mar; 22(136):62. PubMed ID: 23593687
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions.
    Guille C; Sachs G
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1035-9. PubMed ID: 12452523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rectal self-mutilation, rectal bleeding and Prader-Willi syndrome].
    Campeotto F; Naudin C; Viot G; Dupont C
    Arch Pediatr; 2001 Oct; 8(10):1075-7. PubMed ID: 11683099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuing weight-loss effect after topiramate discontinuation in obese persons with schizophrenia: a pilot open-label study.
    Liang CS; Yang FW; Huang SY; Ho PS
    Pharmacopsychiatry; 2014 Jul; 47(4-5):162-8. PubMed ID: 24936804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific treatment of Prader-Willi syndrome through cyclical rehabilitation programmes.
    Grolla E; Andrighetto G; Parmigiani P; Hladnik U; Ferrari G; Bernardelle R; Lago MD; Albarello A; Baschirotto G; Filippi G; Lovato R; Dolcetta D
    Disabil Rehabil; 2011; 33(19-20):1837-47. PubMed ID: 21269146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of add-on topiramate therapy in psychiatric patients with weight gain.
    Cates ME; Feldman JM; Boggs AA; Woolley TW; Whaley NP
    Ann Pharmacother; 2008 Apr; 42(4):505-10. PubMed ID: 18364406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of obesity in Prader-Willi syndrome.
    Butler MG
    Nat Clin Pract Endocrinol Metab; 2006 Nov; 2(11):592-3. PubMed ID: 17082801
    [No Abstract]   [Full Text] [Related]  

  • 31. Maladaptive and compulsive behavior in Prader-Willi syndrome: new insights from older adults.
    Dykens EM
    Am J Ment Retard; 2004 Mar; 109(2):142-53. PubMed ID: 15000675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of fluoxetine in an adolescent with Prader-Willi syndrome.
    Dech B; Budow L
    J Am Acad Child Adolesc Psychiatry; 1991 Mar; 30(2):298-302. PubMed ID: 2016235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prader-Willi Syndrome (PWS) associated to morbid obesity: surgical treatment].
    Braghetto I; Rodríguez A; Debandi A; Brunet L; Papapietro K; Pineda P; Pacheco MI
    Rev Med Chil; 2003 Apr; 131(4):427-31. PubMed ID: 12870238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity.
    Kotwal R; Guerdjikova A; McElroy SL; Keck PE
    Hum Psychopharmacol; 2006 Oct; 21(7):425-31. PubMed ID: 16941522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome in children with Prader-Willi syndrome: the effect of obesity.
    Brambilla P; Crinò A; Bedogni G; Bosio L; Cappa M; Corrias A; Delvecchio M; Di Candia S; Gargantini L; Grechi E; Iughetti L; Mussa A; Ragusa L; Sacco M; Salvatoni A; Chiumello G; Grugni G;
    Nutr Metab Cardiovasc Dis; 2011 Apr; 21(4):269-76. PubMed ID: 20089384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment emergent affective switch with topiramate.
    Tamada RS; Amaral JA; Issler CK; Lafer B
    Braz J Psychiatry; 2006 Jun; 28(2):158. PubMed ID: 16810403
    [No Abstract]   [Full Text] [Related]  

  • 37. Contaminated and unusual food combinations: what do people with Prader-Willi syndrome choose?
    Dykens EM
    Ment Retard; 2000 Apr; 38(2):163-71. PubMed ID: 10804706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral mucosa in children with Prader-Willi syndrome.
    Olczak-Kowalczyk D; Witt A; Gozdowski D; Ginalska-Malinowska M
    J Oral Pathol Med; 2011 Nov; 40(10):778-84. PubMed ID: 21457346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of low-dose topiramate in substance use disorder and bodyweight control.
    Chiu YH; Lee TH; Shen WW
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):630-3. PubMed ID: 18081623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morbid obesity in an adolescent with Prader-Willi syndrome.
    Santos VM; Henrique de Paula F; Osterne EM; Nery NS; Turra TZ
    Rev Med Chil; 2009 Feb; 137(2):264-8. PubMed ID: 19543650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.